Literature DB >> 32186392

Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail.

Andrea L Frump1, Yen-Chun Lai1,2, Tim Lahm1,2,3.   

Abstract

Entities:  

Keywords:  cancer hallmarks; pathogenesis; proliferation; pulmonary vascular disease; treatment

Mesh：

Year:  2020        PMID： 32186392      PMCID： PMC7347276          DOI： 10.1152/ajplung.00084.2020

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN： 1040-0605            Impact factor:   5.464


× No keyword cloud information.
  12 in total

1.  The cancer paradigm of severe pulmonary arterial hypertension.

Authors:  Pradeep R Rai; Carlyne D Cool; Judy A C King; Troy Stevens; Nana Burns; Robert A Winn; Michael Kasper; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

Review 2.  Proliferative Versus Degenerative Paradigms in Pulmonary Arterial Hypertension: Have We Put the Cart Before the Horse?

Authors:  Ketul R Chaudhary; Mohamad Taha; Virgilio J J Cadete; Rafael S Godoy; Duncan J Stewart
Journal:  Circ Res       Date:  2017-04-14       Impact factor: 17.367

3.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.

Authors:  L Taraseviciene-Stewart; Y Kasahara; L Alger; P Hirth; G Mc Mahon ; J Waltenberger; N F Voelkel; R M Tuder
Journal:  FASEB J       Date:  2001-02       Impact factor: 5.191

Review 4.  Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Authors:  Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

5.  Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Authors:  Christophe Guignabert; Carole Phan; Andrei Seferian; Alice Huertas; Ly Tu; Raphaël Thuillet; Caroline Sattler; Morane Le Hiress; Yuichi Tamura; Etienne-Marie Jutant; Marie-Camille Chaumais; Stéphane Bouchet; Benjamin Manéglier; Mathieu Molimard; Philippe Rousselot; Olivier Sitbon; Gérald Simonneau; David Montani; Marc Humbert
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

Review 6.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

7.  Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.

Authors:  Edda Spiekerkoetter; Elena A Goncharova; Christophe Guignabert; Kurt Stenmark; Grazyna Kwapiszewska; Marlene Rabinovitch; Norbert Voelkel; Harm J Bogaard; Brian Graham; Soni S Pullamsetti; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2019-11-20       Impact factor: 3.017

Review 8.  The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later.

Authors:  Carlyne D Cool; Wolfgang M Kuebler; Harm Jan Bogaard; Edda Spiekerkoetter; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-05       Impact factor: 6.011

9.  Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors:  Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690

Review 10.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.